Griffonia

What Is Griffonia?

Griffonia simplicifolia is a woody climbing shrub of West and Central Africa, best known as the richest natural source of 5-HTP (5-hydroxytryptophan) — the direct metabolic precursor to the neurotransmitter serotonin.

Its seeds can contain a remarkably high proportion of 5-HTP, which is why most commercial 5-HTP supplements are extracted from Griffonia rather than synthesised ^{25Reference 25Lemaire PA · 2002An HPLC method for the direct assay of the serotonin precursor 5-hydroxytryptophan in seeds of Griffonia simplicifoliaView study →}. Because 5-HTP raises serotonin synthesis, Griffonia extracts are used in the same contexts as 5-HTP itself: low mood, disturbed sleep, and appetite regulation ^{15,16Reference 15Turner EH et al. · 2006ReviewSerotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan — reviewView study →Reference 16Birdsall TC · 1998ReviewBirdsall TC. (1998). 5-Hydroxytryptophan: a clinically-effective serotonin precursor — review. Alternative Medicine Review. https://pubmed.ncbi.nlm.nih.gov/9727088/View study →}.

Indications

• Low mood and mild depression (as a serotonin precursor)
• Difficulty with sleep onset (via the serotonin → melatonin pathway)
• Appetite and carbohydrate-craving regulation
• Anxiety and fibromyalgia (limited evidence)

Cautions & Safety

Do not combine with SSRIs, SNRIs, MAOIs, triptans, tramadol or other serotonergic drugs without medical supervision, owing to the risk of serotonin syndrome ^{22Reference 22Das YT et al. · 2004ReviewSafety of 5-hydroxy-L-tryptophan — reviewView study →}. Nausea is the most commonly reported side effect and is usually dose-related.

How Is Griffonia Used?

Griffonia is taken almost entirely as a standardised seed extract, dosed by its 5-HTP content rather than by raw herb weight. It’s most often used short-term, on its own or alongside cofactors such as vitamin B6 (needed to convert 5-HTP to serotonin) and magnesium.

Traditional Uses

In parts of West Africa the leaves, stems and seeds of Griffonia have a history of folk use — the stems as chewing sticks, and various preparations applied to wounds or used for digestive complaints. Its modern prominence, however, comes almost entirely from the isolation of 5-HTP from its seeds rather than from a classical materia medica tradition.

Botanical Information

Griffonia simplicifolia is a member of the Leguminosae (legume family), a large climbing shrub reaching several metres, with greenish flowers and black seed pods. It’s native to the coastal forests and savannah of West and Central Africa, including Ghana and the Ivory Coast.

Phytochemistry

Griffonia simplicifolia is phytochemically unusual in being dominated by a single small molecule: 5-hydroxytryptophan (5-HTP), the direct precursor to serotonin. It is the seed’s defining constituent and the reason the plant is grown commercially — ripe seeds typically contain about 14–20% 5-HTP by weight, with figures as high as ~20.8% recorded in Ghanaian material ^{25Reference 25Lemaire PA · 2002An HPLC method for the direct assay of the serotonin precursor 5-hydroxytryptophan in seeds of Griffonia simplicifoliaView study →}. (Commercial “98–99%” extracts are concentrated and purified, not the raw seed value.) The seeds also carry the well-known Griffonia simplicifolia lectins (GSL-I and GSL-II), carbohydrate-binding proteins widely used as laboratory reagents, along with minor β-carboline alkaloids such as griffonine ^{26,27Reference 26Vigliante I et al. · 2019Chemical characterization and DNA fingerprinting of Griffonia simplicifolia BaillView study →Reference 27Wang XZ et al. · 2013A new β-carboline alkaloid from the seeds of Griffonia simplicifoliaView study →}, and extract-dependent flavonoids, flavan-3-ols and seed-oil fatty acids ^{19,26Reference 19Mannino G et al. · 2023In vitroBiological activity and metabolomics of Griffonia simplicifolia seeds extracted with different methodologies — in vitro. https://pubmed.ncbi.nlm.nih.gov/37760012/View study →Reference 26Vigliante I et al. · 2019Chemical characterization and DNA fingerprinting of Griffonia simplicifolia BaillView study →}.

Constituent Summary

5-HTP figure is % of seed dry weight; varies with seed ripeness and provenance. Lectins and griffonine are present but not quantified here.

Pharmacology & Research

Griffonia simplicifolia is a rare case in phytotherapy: it is not really studied as a whole herb at all. It is grown, standardised and dosed as a botanical delivery vehicle for a single small molecule — 5-hydroxytryptophan (5-HTP), the immediate precursor to serotonin — and almost the entire human literature concerns purified 5-HTP rather than whole-seed extract ^{15,16,25Reference 15Turner EH et al. · 2006ReviewSerotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan — reviewView study →Reference 16Birdsall TC · 1998ReviewBirdsall TC. (1998). 5-Hydroxytryptophan: a clinically-effective serotonin precursor — review. Alternative Medicine Review. https://pubmed.ncbi.nlm.nih.gov/9727088/View study →Reference 25Lemaire PA · 2002An HPLC method for the direct assay of the serotonin precursor 5-hydroxytryptophan in seeds of Griffonia simplicifoliaView study →}. That literature is modest and dated: several small randomised trials in depression, fibromyalgia, appetite/weight and panic, most from the 1980s–90s, generally positive but methodologically weak, with a Cochrane review judging the depression evidence insufficient despite a positive pooled signal ^{1,2Reference 1Shaw K et al. · 2002Systematic reviewTryptophan and 5-hydroxytryptophan for depression — systematic reviewView study →Reference 2Shaw K et al. · 2002Meta-analysisAre tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysisView study →}. Studies that used the actual Griffonia seed extract, rather than isolated 5-HTP, are overwhelmingly preclinical (rat anxiolytic and reproductive-behaviour models, a mouse candidiasis model, cell-line antioxidant and antiproliferative work) ^{17,18,19,20Reference 17Carnevale G et al. · 2011AnimalAnxiolytic-like effect of Griffonia simplicifolia Baill. seed extract in rats — animal modelView study →Reference 18Carnevale G et al. · 2010AnimalGriffonia simplicifolia negatively affects sexual behavior in female rats — animal modelView study →Reference 19Mannino G et al. · 2023In vitroBiological activity and metabolomics of Griffonia simplicifolia seeds extracted with different methodologies — in vitro. https://pubmed.ncbi.nlm.nih.gov/37760012/View study →Reference 20Puccetti M et al. · 2025AnimalGriffonia simplicifolia seeds extract rich in 5-hydroxy-L-tryptophan reduces infection and inflammation in a mouse model of vulvovaginal candidiasis — animal modelView study →}. The honest reading is that Griffonia’s clinical credibility is borrowed from 5-HTP pharmacology, and transfers only insofar as a given seed extract delivers an equivalent, clean dose of 5-HTP.

0. Evidence by indication

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric, and I’ll keep honing the formula over time. Each indication name links down to its write-up. Read the scores as evidence for 5-HTP delivered by Griffonia, not the whole herb — the two are only as interchangeable as a given extract’s 5-HTP content and purity make them.

Indication	Support	Rests on
Depression & low mood	██████░░░░ 62%	Several small 5-HTP RCTs + a positive but low-quality Cochrane/meta signal; purified 5-HTP, not whole extract.
Appetite & weight regulation	██████░░░░ 60%	Small 5-HTP RCTs showing early satiety and weight loss; one used a plant-extract spray.
Fibromyalgia	██████░░░░ 57%	One double-blind placebo RCT (n=50) + one 90-day open study, both positive, both old; 5-HTP.
Anxiety & panic	█████░░░░░ 50%	A positive 5-HTP CO₂-panic challenge RCT plus rat data using actual Griffonia extract.
Migraine prophylaxis	█████░░░░░ 47%	Adult data positive vs active comparators, but the placebo-controlled childhood trial was null.
Sleep onset	████░░░░░░ 44%	Serotonin→melatonin mechanism + old sleep-architecture data; no modern insomnia RCT of the extract.
Antioxidant	███░░░░░░░ 30%	In-vitro seed-extract assays only; solvent-dependent, no human data.
Immunomodulatory & anti-infective	███░░░░░░░ 30%	Single mouse vulvovaginal-candidiasis model using Griffonia extract.
Anticancer	███░░░░░░░ 28%	Osteosarcoma and other cell lines only; constituent- and extract-level, no in-vivo tumour data.

1. Depression & low mood

This is the most-studied indication and the origin of Griffonia’s reputation. A Cochrane review of 5-HTP and tryptophan for depression found only two trials (64 patients total) of adequate quality; pooled, they favoured the precursors over placebo (Peto OR ≈ 4.1, 95% CI 1.3–13.2), but the reviewers judged the evidence insufficient because of small size and probable publication bias among ~100 excluded low-quality studies ^{1,2Reference 1Shaw K et al. · 2002Systematic reviewTryptophan and 5-hydroxytryptophan for depression — systematic reviewView study →Reference 2Shaw K et al. · 2002Meta-analysisAre tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysisView study →}. Later randomised trials are more encouraging but still small and often use active comparators rather than placebo: 5-hydroxytryptophan matched fluoxetine over 8 weeks in first-episode depression (n=60) ^{3Reference 3Jangid P et al. · 2013RCTComparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in first depressive episode — randomised double-blind trialView study →} and performed comparably to fluvoxamine ^{4Reference 4Pöldinger W et al. · 1991RCTA functional-dimensional approach to depression: 5-hydroxytryptophan versus fluvoxamine — randomised multicentre trialView study →}, while a small placebo-controlled crossover trial in Parkinson’s disease (n=25, 50 mg/day) reported improvement in depressive and apathy scores ^{5Reference 5Meloni M et al. · 2020RCTEfficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson’s disease — randomised, double-blind, placebo-controlled crossover trialView study →}. Every one of these used purified 5-HTP; none tested whole Griffonia seed extract.

Gap: no adequately powered, modern, placebo-controlled trial; and no depression trial has used the whole-seed extract that consumers actually buy.

2. Appetite & weight regulation

5-HTP’s satiety effect has the most internally consistent human signal. In a double-blind RCT, obese adults given 5-hydroxytryptophan 900 mg/day over two 6-week periods lost significant weight, reduced carbohydrate intake and reported early satiety, both with and without a prescribed diet ^{8Reference 8Cangiano C et al. · 1992RCTEating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan — randomised controlled trialView study →}. A separate double-blind RCT in overweight women used a plant-extract sublingual spray naturally containing 5-HTP and reported increased satiety with confirmed 5-HTP bioavailability (urinary 5-HIAA) over 8 weeks ^{9Reference 9Rondanelli M et al. · 2009RCTSatiety and amino-acid profile in overweight women after a natural plant-extract (5-hydroxytryptophan) sublingual spray — randomised, double-blind, placebo-controlled trialView study →} — one of the few human trials to use a botanical preparation rather than the pure molecule. The mechanism (post-prandial serotonergic satiety signalling) is coherent, but sample sizes are small and long-term weight-maintenance data are absent.

Gap: short trials, small samples, no durability data; nausea at the higher (900 mg) doses limits tolerability.

3. Fibromyalgia

Two Italian studies underpin this use. A double-blind, placebo-controlled trial in 50 patients with primary fibromyalgia found that 5-hydroxytryptophan significantly improved tender-point count, pain, sleep, anxiety and fatigue, with only mild transient side-effects ^{6Reference 6Caruso I et al. · 1990RCTDouble-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome — randomised controlled trialView study →}; a subsequent 90-day open study in another 50 patients reported significant improvement across the same variables and sustained effect, with ~30% reporting (mostly minor) side-effects ^{7Reference 7Sarzi Puttini P · 1992Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open studyView study →}. The signal is consistent and the mechanism plausible given serotonin’s role in central pain modulation and sleep, but the evidence is two small studies from a single group, one uncontrolled, and now three decades old.

Gap: no replication outside the original investigators, no placebo-controlled confirmation since 1990, and no whole-extract data.

4. Anxiety & panic

The clearest human anxiety signal is a challenge-model RCT: 200 mg L-5-hydroxytryptophan significantly blunted the reaction to a 35% CO₂ panic challenge in 24 panic-disorder patients (subjective anxiety, panic-symptom score and number of attacks) but not in healthy controls ^{10Reference 10Schruers K et al. · 2002RCTAcute L-5-hydroxytryptophan administration inhibits carbon-dioxide-induced panic in panic disorder patients — randomised controlled trialView study →}. An older double-blind comparison of 5-HTP, clomipramine and placebo in anxiety disorders provides supporting but weaker evidence ^{11Reference 11Kahn RS · 1987RCTEffect of a serotonin precursor and uptake inhibitor in anxiety disorders: a double-blind comparison of 5-hydroxytryptophan, clomipramine and placeboView study →}. Uniquely for this indication, there is also a study using the actual herb: Griffonia seed extract (10 and 25 mg/kg) increased time in the light compartment in a rat dark–light test, the first published in-vivo evidence that the extract itself has anxiolytic activity ^{17Reference 17Carnevale G et al. · 2011AnimalAnxiolytic-like effect of Griffonia simplicifolia Baill. seed extract in rats — animal modelView study →}. A companion rat study is a caution flag rather than a benefit — the same extract reduced receptive/proceptive sexual behaviour in female rats at higher doses ^{18Reference 18Carnevale G et al. · 2010AnimalGriffonia simplicifolia negatively affects sexual behavior in female rats — animal modelView study →}.

Gap: human data are a single acute challenge model, not a treatment trial; the direct-herb evidence is rodent-only.

5. Migraine prophylaxis

Migraine is where the evidence is genuinely mixed. In adults, an RCT of 124 migraineurs found 5-hydroxytryptophan improved attacks in ~71% of patients — comparable to methysergide (~75%) and better tolerated — but this used an active comparator with no placebo arm ^{12Reference 12Titus F et al. · 1986RCTTitus F, Dávalos A, Alom J, Codina A. (1986). 5-Hydroxytryptophan versus methysergide in the prophylaxis of migraine — randomised clinical trial. European Neurology. https://pubmed.ncbi.nlm.nih.gov/3536521/View study →}, and a separate trial reported it comparable to propranolol. The key limiter is the paediatric evidence: a double-blind, placebo-controlled crossover trial in children (5 mg/kg/day) found that both 5-HTP and placebo reduced migraine index, with no significant difference between them ^{13Reference 13Santucci M et al. · 1986RCTL-5-hydroxytryptophan versus placebo in childhood migraine prophylaxis — double-blind crossover studyView study →}. So the adult “positive vs active drug” picture is undercut by a null result against placebo in children.

Gap: no adult placebo-controlled trial; the one rigorous placebo comparison (paediatric) was negative, consistent with a large placebo response in migraine.

6. Sleep onset

The sleep rationale is mechanistic: serotonin is the biosynthetic precursor to melatonin, so raising serotonin synthesis is argued to support sleep onset ^{16Reference 16Birdsall TC · 1998ReviewBirdsall TC. (1998). 5-Hydroxytryptophan: a clinically-effective serotonin precursor — review. Alternative Medicine Review. https://pubmed.ncbi.nlm.nih.gov/9727088/View study →}. Direct human evidence is thin and old — early work showed 5-hydroxytryptophan alters sleep architecture (notably REM) in normal subjects ^{14Reference 14Wyatt RJ et al. · 1971Clinical trialEffects of 5-hydroxytryptophan on the sleep of normal human subjects — clinical trialView study →} — but there is no modern, placebo-controlled insomnia trial of Griffonia extract, and the appetite/mood trials did not use validated sleep endpoints as primary outcomes. Sleep improvement is often reported as a secondary benefit within fibromyalgia and mood studies rather than tested directly.

Gap: no dedicated insomnia RCT of the extract; the claim leans on mechanism and secondary outcomes.

7. Antioxidant

Antioxidant activity is a property of the seed extract measured in the test tube, not a clinical outcome. A metabolomics study characterising Griffonia seed extracts across solvents (water, acetone, methanol, ethanol) and extraction methods reported antioxidant, antiproliferative and antimicrobial activity, with radical-scavenging capacity tracking the flavonoid and flavan-3-ol content that acetone/ethanol extracted best ^{19Reference 19Mannino G et al. · 2023In vitroBiological activity and metabolomics of Griffonia simplicifolia seeds extracted with different methodologies — in vitro. https://pubmed.ncbi.nlm.nih.gov/37760012/View study →}. This is useful for understanding the extract’s chemistry but says nothing about systemic antioxidant effects at ingested doses.

Gap: in-vitro only, solvent- and method-dependent, no bioavailability or human data; the effect may not survive digestion at realistic doses.

8. Immunomodulatory & anti-infective

This is a newer, herb-specific line of work. A 2025 study optimised 5-HTP yield from Griffonia seed by high-power ultrasonic extraction and tested the extract in a mouse model of vulvovaginal candidiasis, reporting reduced infection and inflammation attributed to serotonin’s known immunomodulatory activity, then formulated it as a vaginal preparation ^{20Reference 20Puccetti M et al. · 2025AnimalGriffonia simplicifolia seeds extract rich in 5-hydroxy-L-tryptophan reduces infection and inflammation in a mouse model of vulvovaginal candidiasis — animal modelView study →}. It is a single, mechanistically-motivated animal study rather than a body of evidence, and the effect is inferred to run through serotonin signalling rather than a direct antifungal action.

Gap: one animal model, one group; no human data and no confirmation that the immunomodulatory effect is clinically meaningful.

9. Anticancer

Antitumour interest is entirely preclinical and cell-line based. A hydroalcoholic (ethanol/water 70:30) Griffonia seed extract showed cytotoxic and antimetastatic activity against osteosarcoma cell lines and was explored for interaction with chemotherapy targeting ^{21Reference 21Bellavia D et al. · 2026In vitroAntimetastatic effects of a Griffonia simplicifolia seed extract in osteosarcoma cell lines — in vitroView study →}, and the metabolomics study above also reported antiproliferative activity in vitro ^{19Reference 19Mannino G et al. · 2023In vitroBiological activity and metabolomics of Griffonia simplicifolia seeds extracted with different methodologies — in vitro. https://pubmed.ncbi.nlm.nih.gov/37760012/View study →}. These are early screening results in cultured cells; there is no animal tumour-model or human evidence, and the concentrations used in vitro may not be achievable systemically.

Gap: cell-line only, no in-vivo tumour data, no pharmacokinetic bridge to achievable human exposures.

Mechanisms

Mechanism	Drives	Key compounds
Bypasses rate-limiting tryptophan hydroxylase; crosses the blood–brain barrier; raises central and peripheral serotonin (5-HT) synthesis, feeding the serotonin→melatonin pathway	depression, appetite/satiety, fibromyalgia, anxiety/panic, migraine, sleep	5-hydroxytryptophan
Minor seed alkaloids; potential neuromodulatory activity, largely uncharacterised pharmacologically (chemotaxonomic marker)	none established	griffonine
Carbohydrate-binding proteins (α-D-galactosyl / N-acetylglucosamine specificity); laboratory reagents, not an ingestion-relevant activity	none (research tool, not a therapeutic mechanism)	GSL-I, GSL-II lectins
Radical scavenging in vitro; oxidative-stress modulation as a class	antioxidant, antiproliferative (in-vitro only)	flavonoids / flavan-3-ols (minor, extract-dependent)

Clinical trials

Registered trials overwhelmingly test isolated 5-HTP, not Griffonia seed extract. On ClinicalTrials.gov only one registered interventional trial uses Griffonia simplicifolia itself as the intervention (NCT06893822, recruiting, chronic pain / central sensitisation); the remainder of the serotonin-precursor register concerns purified 5-HTP across mood, body composition, sleep, IBD fatigue and neurological indications, plus one published open-label pediatric study of a Griffonia/magnesium complex ^{28Reference 28Esposito M et al. · 2015A medical-food formulation of Griffonia simplicifolia/magnesium for childhood periodic syndrome therapy — open-label studyView study →}.

Completed	Planned	Terminated	Preclinical
~20+ (5-HTP, all indications)	~6 recruiting + 1 Griffonia-extract trial (NCT06893822)	0	~6 (Griffonia extract: rat, mouse, cell line)

Last checked: July 2025.

Dosage

Griffonia is dosed by 5-HTP content. Extracts standardised to roughly 20–30% 5-HTP are typical, providing about 50–300 mg of 5-HTP per day in divided doses. Starting low and taking it with food reduces nausea.

Research Doses

These figures describe doses used in trials of purified 5-HTP (the molecule Griffonia delivers), not a recommendation, and most were not run on whole-seed extract.

Indication	5-HTP dose (trials)	Reference
Depression	150–300 mg/day (vs fluoxetine/fluvoxamine); 50 mg/day (Parkinson’s)	3,4,5Reference 3Jangid P et al. · 2013RCTComparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in first depressive episode — randomised double-blind trialView study →Reference 4Pöldinger W et al. · 1991RCTA functional-dimensional approach to depression: 5-hydroxytryptophan versus fluvoxamine — randomised multicentre trialView study →Reference 5Meloni M et al. · 2020RCTEfficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson’s disease — randomised, double-blind, placebo-controlled crossover trialView study →
Obesity / appetite	up to 900 mg/day (higher nausea)	8Reference 8Cangiano C et al. · 1992RCTEating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan — randomised controlled trialView study →
Fibromyalgia	300 mg/day	6,7Reference 6Caruso I et al. · 1990RCTDouble-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome — randomised controlled trialView study →Reference 7Sarzi Puttini P · 1992Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open studyView study →
Anxiety / panic	200 mg acute (CO₂ challenge)	10Reference 10Schruers K et al. · 2002RCTAcute L-5-hydroxytryptophan administration inhibits carbon-dioxide-induced panic in panic disorder patients — randomised controlled trialView study →
Migraine (adult)	~600 mg/day; (childhood) 5 mg/kg/day	12,13Reference 12Titus F et al. · 1986RCTTitus F, Dávalos A, Alom J, Codina A. (1986). 5-Hydroxytryptophan versus methysergide in the prophylaxis of migraine — randomised clinical trial. European Neurology. https://pubmed.ncbi.nlm.nih.gov/3536521/View study →Reference 13Santucci M et al. · 1986RCTL-5-hydroxytryptophan versus placebo in childhood migraine prophylaxis — double-blind crossover studyView study →

Caveat: higher doses (≥900 mg/day) markedly increase gastrointestinal intolerance; carbidopa co-administration has historically been used to reduce peripheral decarboxylation and nausea, but is not present in over-the-counter Griffonia extracts.

Traditional Dosage

Griffonia has minimal classical materia medica tradition; there is no established traditional dose. In West African folk use the stems, leaves and seeds were used in unstandardised preparations. Modern use is driven entirely by the seed’s 5-HTP content rather than a traditional posology.

Safety

Griffonia is dosed by its 5-hydroxytryptophan (5-HTP) content, and its safety profile is essentially that of 5-HTP: generally well tolerated at common doses, with nausea and gastrointestinal upset the most frequent, dose-related complaints ^{22Reference 22Das YT et al. · 2004ReviewSafety of 5-hydroxy-L-tryptophan — reviewView study →}. The principal risk is serotonergic: it should not be combined with SSRIs, SNRIs, MAOIs, triptans, tramadol or other serotonergic agents (including dextromethorphan, linezolid and St John’s Wort) without medical supervision, because of the risk of serotonin syndrome ^{22Reference 22Das YT et al. · 2004ReviewSafety of 5-hydroxy-L-tryptophan — reviewView study →}. A distinct historical concern is contamination — a family of trace contaminants (“Peak X”, characterised as 4,5-tryptophan-dione and related species) has been detected in commercial 5-HTP and is chemically related to the contaminant implicated in the 1989 L-tryptophan eosinophilia-myalgia syndrome (EMS) outbreak; no definitive causal EMS case has been established for 5-HTP, but the signal argues for pharmaceutical-grade, tested material ^{22,23,24Reference 22Das YT et al. · 2004ReviewSafety of 5-hydroxy-L-tryptophan — reviewView study →Reference 23Klarskov K et al. · 1999Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophanView study →Reference 24Klarskov K et al. · 2003Structural characterization of a case-implicated contaminant, “Peak X,” in commercial 5-hydroxytryptophanView study →}. Some formulations add carbidopa to reduce peripheral decarboxylation and nausea; this raises CNS bioavailability and its own interaction considerations. Discontinue before scheduled surgery.

Herb–drug interaction assessment here is pharmacodynamic (serotonergic), not pharmacokinetic: no dedicated CYP450 or herb–drug metabolic interaction study of Griffonia extract was identified. The absence of such studies should not be read as evidence of safety.

Pregnancy & lactation

Avoid — not established. Griffonia/5-HTP has not been formally evaluated in pregnancy or lactation. Given its serotonergic activity and the absence of safety data, avoid it during pregnancy and breastfeeding. This is a precaution based on unstudied status and mechanism, not evidence of harm — and equally not evidence of safety.

References

1. Shaw K, Turner J, Del Mar C. (2002). Tryptophan and 5-hydroxytryptophan for depression — systematic review. Cochrane Database of Systematic Reviews. https://pubmed.ncbi.nlm.nih.gov/11687048/
2. Shaw K, Turner J, Del Mar C. (2002). Are tryptophan and 5-hydroxytryptophan effective treatments for depression? A meta-analysis. Australian & New Zealand Journal of Psychiatry. https://pubmed.ncbi.nlm.nih.gov/12169147/
3. Jangid P, Malik P, Singh P, et al. (2013). Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in first depressive episode — randomised double-blind trial. Asian Journal of Psychiatry. https://pubmed.ncbi.nlm.nih.gov/23380314/
4. Pöldinger W, Calanchini B, Schwarz W. (1991). A functional-dimensional approach to depression: 5-hydroxytryptophan versus fluvoxamine — randomised multicentre trial. Psychopathology. https://pubmed.ncbi.nlm.nih.gov/1909444/
5. Meloni M, Puligheddu M, Carta M, et al. (2020). Efficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson’s disease — randomised, double-blind, placebo-controlled crossover trial. European Journal of Neurology. https://pubmed.ncbi.nlm.nih.gov/32067288/
6. Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. (1990). Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome — randomised controlled trial. Journal of International Medical Research. https://pubmed.ncbi.nlm.nih.gov/2193835/
7. Sarzi Puttini P, Caruso I. (1992). Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. Journal of International Medical Research. https://pubmed.ncbi.nlm.nih.gov/1521674/
8. Cangiano C, Ceci F, Cascino A, et al. (1992). Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan — randomised controlled trial. American Journal of Clinical Nutrition. https://pubmed.ncbi.nlm.nih.gov/1384305/
9. Rondanelli M, Klersy C, Iadarola P, et al. (2009). Satiety and amino-acid profile in overweight women after a natural plant-extract (5-hydroxytryptophan) sublingual spray — randomised, double-blind, placebo-controlled trial. International Journal of Obesity. https://pubmed.ncbi.nlm.nih.gov/19752879/
10. Schruers K, van Diest R, Overbeek T, Griez E. (2002). Acute L-5-hydroxytryptophan administration inhibits carbon-dioxide-induced panic in panic disorder patients — randomised controlled trial. Psychiatry Research. https://pubmed.ncbi.nlm.nih.gov/12559480/
11. Kahn RS, Westenberg HG. (1987). Effect of a serotonin precursor and uptake inhibitor in anxiety disorders: a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. International Clinical Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/3312397/
12. Titus F, Dávalos A, Alom J, Codina A. (1986). 5-Hydroxytryptophan versus methysergide in the prophylaxis of migraine — randomised clinical trial. European Neurology. https://pubmed.ncbi.nlm.nih.gov/3536521/
13. Santucci M, Cortelli P, Rossi PG, et al. (1986). L-5-hydroxytryptophan versus placebo in childhood migraine prophylaxis — double-blind crossover study. Cephalalgia. https://pubmed.ncbi.nlm.nih.gov/3533271/
14. Wyatt RJ, Zarcone V, Engelman K, et al. (1971). Effects of 5-hydroxytryptophan on the sleep of normal human subjects — clinical trial. Electroencephalography and Clinical Neurophysiology. https://pubmed.ncbi.nlm.nih.gov/4105646/
15. Turner EH, Loftis JM, Blackwell AD. (2006). Serotonin a la carte: supplementation with the serotonin precursor 5-hydroxytryptophan — review. Pharmacology & Therapeutics. https://pubmed.ncbi.nlm.nih.gov/16023217/
16. Birdsall TC. (1998). 5-Hydroxytryptophan: a clinically-effective serotonin precursor — review. Alternative Medicine Review. https://pubmed.ncbi.nlm.nih.gov/9727088/
17. Carnevale G, Di Viesti V, Zavatti M, Zanoli P. (2011). Anxiolytic-like effect of Griffonia simplicifolia Baill. seed extract in rats — animal model. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/21353511/
18. Carnevale G, Di Viesti V, Zavatti M, et al. (2010). Griffonia simplicifolia negatively affects sexual behavior in female rats — animal model. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/20359873/
19. Mannino G, Gentile C, Porcu A, et al. (2023). Biological activity and metabolomics of Griffonia simplicifolia seeds extracted with different methodologies — in vitro. https://pubmed.ncbi.nlm.nih.gov/37760012/
20. Puccetti M, Pariano M, Costantini C, et al. (2025). Griffonia simplicifolia seeds extract rich in 5-hydroxy-L-tryptophan reduces infection and inflammation in a mouse model of vulvovaginal candidiasis — animal model. Journal of Pharmacy and Pharmacology. https://pubmed.ncbi.nlm.nih.gov/40414710/
21. Bellavia D, Naselli F, Serio G, et al. (2026). Antimetastatic effects of a Griffonia simplicifolia seed extract in osteosarcoma cell lines — in vitro. Antioxidants, 15(2):263. https://doi.org/10.3390/antiox15020263
22. Das YT, Bagchi M, Bagchi D, Preuss HG. (2004). Safety of 5-hydroxy-L-tryptophan — review. Toxicology Letters. https://pubmed.ncbi.nlm.nih.gov/15068828/
23. Klarskov K, Johnson KL, Benson LM, et al. (1999). Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan. Advances in Experimental Medicine and Biology. https://pubmed.ncbi.nlm.nih.gov/10721089/
24. Klarskov K, Johnson KL, Benson LM, et al. (2003). Structural characterization of a case-implicated contaminant, “Peak X,” in commercial 5-hydroxytryptophan. Journal of Rheumatology. https://pubmed.ncbi.nlm.nih.gov/12508395/
25. Lemaire PA, Adosraku RK. (2002). An HPLC method for the direct assay of the serotonin precursor 5-hydroxytryptophan in seeds of Griffonia simplicifolia. Phytochemical Analysis. https://pubmed.ncbi.nlm.nih.gov/12494751/
26. Vigliante I, Mannino G, Maffei ME. (2019). Chemical characterization and DNA fingerprinting of Griffonia simplicifolia Baill. Molecules. https://pubmed.ncbi.nlm.nih.gov/30875930/
27. Wang XZ, Xia YM, et al. (2013). A new β-carboline alkaloid from the seeds of Griffonia simplicifolia. Chinese Journal of Natural Medicines. https://pubmed.ncbi.nlm.nih.gov/23845550/
28. Esposito M, Precenzano F, Bitetti I, et al. (2015). A medical-food formulation of Griffonia simplicifolia/magnesium for childhood periodic syndrome therapy — open-label study. Journal of Medicinal Food. https://pubmed.ncbi.nlm.nih.gov/25590358/